3252
J. A. Pfefferkorn et al. / Bioorg. Med. Chem. Lett. 19 (2009) 3247–3252
Disease. From Basics to Novel Therapeutics; Matschinsky, F.M., Magnuson, M.A.,
20. Beszant, S.; Giannini, E.; Zanoni, G.; Vidari, G. Eur. J. Org. Chem. 2003, 20, 3958.
21. Basha, A.; Lipton, M.; Weinreb, S. M. Tetrahedron Lett. 1977, 48, 4171.
22. Menche, D.; Hassfeld, J.; Li, J.; Rudolph, S. J. Am. Chem. Soc. 2007, 129, 6100.
23. Biochemical activation assay was conducted using purified recombinant
human glucokinase prepared as previously described, see: Ralph, E. C.;
Thompson, J.; Sun, S. Biochemistry 2008, 47, 5028. The 6.5 mM glucose
concentration was selected to offer an optimal window to measure
activation relative to basal enzyme activity. Evaluation of selected activators
at higher glucose concentrations confirmed that these analogs continued to
activate the enzyme up to 100 mM glucose. An assay protocol is provided in
the Supplementary data..
Eds.; Karger: Basel, 2004; Vol. 16, p 155.; (c) Matschinsky, F. M. Diabetes 1996,
45, 223; (d) Matschinsky, F. M.; Glaser, B.; Magnuson, M. A. Diabetes 1998, 47,
307.
6. (a) Dunn-Meynell, A. A.; Routh, V. H.; Kang, L.; Gaspers, L.; Levin, B. E. Diabetes
2002, 51, 2056; (b) Kang, L.; Dunn-Meynell, A. A.; Routh, V. H.; Gaspers, L. D.;
Nagata, Y.; Nishimura, T.; Eiki, J.; Zhang, B. B.; Levin, B. E. Diabetes 2006, 55, 412.
7. Reimann, F.; Gribble, F. M. Diabetes 2002, 51, 2757.
8. For a review, see: Iynedjian, P. B. Cell. Mol. Life Sci. 2009, 66, 27.
9. Grimsby, J.; Sarabu, R.; Corbett, W. L.; Haynes, N. E.; Bizzarro, F. T.; Coffey, J. W.;
Guertin, K. R.; Hilliard, D. W.; Kester, R. F.; Mahaney, P. E.; Marcus, L.; Qi, L.;
Spence, C. L.; Tengi, J.; Magnuson, M. A.; Chu, C. A.; Dvorozniak, M. T.;
Matschinsky, F. M.; Grippo, J. F. Science 2003, 301, 370.
24. Experimental procedures for microsomal and hepatocyte incubations and
metabolite identification are provided in the Supplementary data..
10. Fyfe, M. C.; White, J. R.; Taylor, A.; Chatfield, R.; Wargent, E.; Printz, R. L.;
Sulpice, T.; McCormack, J. G.; Procter, M. J.; Reynet, C.; Widdowson, P. S.;
Wong-Kai-In, P. Diabetologia 2007, 50, 1277.
11. (a) Nishimura, T.; Iino, T.; Nagata, Y.; Eiki, J. WO2003080585.; (b) Mitsuya, M.;
Kamata, K.; Bamba, M.; Watanabe, H.; Sasaki, Y.; Sasaki, K.; Ohyama, S.;
Hosaka, H.; Nagata, Y.; Eiki, J.; Nishimura, T. Bioorg. Med. Chem. 2009, doi:
12. McKerrecher, D.; Allen, J. V.; Caulkett, P. W. R.; Donald, C. S.; Fenwick, M. L.;
Grange, E.; Johnson, K. M.; Johnstone, C.; Jones, C. D.; Pike, K. G.; Rayner, J. W.;
Walker, R. P. Bioorg. Med. Chem. Lett. 2006, 16, 2705.
13. Zhi, J.; Zhai, S.; Mulligan, M. -E.; Grimsby, J.; Arbet-Engels, C.; Boldrin, M.;
Balena, R. Presentation 42, 2008 EASD 44th Annual Meeting, Rome, Italy..
14. Goodnow, R. J.; Le, K. F. WO200183465..
25. A review of the literature did not reveal similar examples of glutathione
conjugate formation with 4-sulfonyl-2-pyridones. However, glutathione
displacement of a sulfonamides have been reported on other heterocycles,
for examples see: (a) Graham, S. L.; Shepard, K. L.; Anderson, P. S.; Baldwin, J. J.;
Best, D. B.; Christy, M. E.; Freedman, M. B.; Gautheron, P.; Habecker, C. N.;
Hoffman, J. M.; Lyle, P. A.; Michelson, S. R.; Ponticello, G. S.; Robb, C. M.;
Schwam, H.; Smith, A. M.; Smith, R. L.; Sondey, J. M.; Strohmaier, K. M.; Sugrue,
M. F.; Varga, S. L. J. Med. Chem. 1989, 32, 2548; (b) Graham, S. L.; Hoffman, J. M.;
Gautheron, P.; Michelson, S. R.; Scholz, T. H.; Schwam, H.; Shepard, K. L.; Smith,
A. M.; Smith, R. L.; Sondey, J. M. J. Med. Chem. 1990, 33, 749; (c) Zhao, Z.;
Koeplinger, K. A.; Peterson, T.; Conradi, R. A.; Burton, P. S.; Suarato, A.;
Heinrikson, R. L.; Tomasselli, A. G. Drug Metab. Dispos. 1999, 27, 992;
Additionally,
a glutathione conjugate of a 2-pyridone ring system was
15. Guertin, K. R. F. WO200248106..
16. Cao, S. X.; Feng, J.; Gwaltney, S. L.; Hosfield, D. J.; Skene, R. J.; Stafford, J. A.;
Tang, M. US20072811942..
reported during biotransformation studies of the cardiotonic agent
amrinone; however, in this case, the conjugate occurred at the 6-position of
the 2-pyridone rather than the 4-position observed in the current studies. See:
Baker, J. F.; Chalecki, D. P.; Benziger, P. E.; O’Melia, S. D.; Clemans, S. D.;
Edelson, J. Drug Metab. Dispos. 1982, 10, 168.
17.
A
patent application describing structurally similar pyridone-based
glucokinase activators has recently published, see: Cheruvallath, Z.; Feng, J.;
Guntupalli, P.; Gwaltney, S. L.; Miura, J.; Sabat, M.; Tang, M.; Wang, H.
WO2008079787..
26. Gericke, R.; Beirer, N.; Wilm, C. WO2003051866..
27. Gijsen, H. J. M.; De Cleyn, M. A. J.; Surkyn, M.; Verbist, B. M. P. WO2008003665..
28. Bantick, J. R.; Beaton, H. G.; Cooper, S. L.; Hill, S.; Hirst, S. C.; McInally, T.;
Spencer, J.; Tinker, A. C.; Willis, P. A. Bioorg. Med. Chem. Lett. 1994, 4, 121.
18. Minich, M. L.; Watson, I. D.; Filipski, K. J.; Pfefferkorn, J. A. Tetrahedron Lett.
2009, 50, 2094.
19. (a) Effenberger, F.; Maier, R.; Schoenwaelder, K.-H.; Ziegler, T. Chem. Ber. 1982,
115, 2766; (b) Effenberger, F.; Ziegler, T.; Schoenwaelder, K.-H. Chem. Ber. 1985,
118, 741.